| PFEIFER, H., G. CAZZANIGA, V. H. J VAN DER VELDEN, J. M. CAYUELE, B. SCHAFER, O. SPINELLI, S. AKIKI, S. AVIGAD, I. BENDIT, K. BORG, H. CAVE, L. ELIA, S. C. RESHMI, G. GERRARD, S. HAYETTE, M. HERMANSON, A. JUH, Tomáš JURČEK, M. C. CHILLON, C. HOMBURG, G. MARTINELLI, V. KAIRISTO, T. LANGEN, T. LION, M. C. MUELLER, F. PANE, L. RAI, C. DAMM-WELK, T. SACHA, S. SCHNITTGER, T. TOULOUMENIDOU, H. VALERHAUGEN, P. VANDENBERGHE, J. ZUNA, H. SERVER, E. HERRMANN, S. MARKOVIC, J. J. M VAN DONGEN a O. G. OTTMANN. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. London: Nature Publishing Group, 2019, roč. 33, č. 8, s. 1910-1922. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-019-0413-0. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1593316,
author = {Pfeifer, H. and Cazzaniga, G. and van der Velden, V. H. J and Cayuele, J. M. and Schafer, B. and Spinelli, O. and Akiki, S. and Avigad, S. and Bendit, I. and Borg, K. and Cave, H. and Elia, L. and Reshmi, S. C. and Gerrard, G. and Hayette, S. and Hermanson, M. and Juh, A. and Jurček, Tomáš and Chillon, M. C. and Homburg, C. and Martinelli, G. and Kairisto, V. and Langen, T. and Lion, T. and Mueller, M. C. and Pane, F. and Rai, L. and DammandWelk, C. and Sacha, T. and Schnittger, S. and Touloumenidou, T. and Valerhaugen, H. and Vandenberghe, P. and Zuna, J. and Server, H. and Herrmann, E. and Markovic, S. and van Dongen, J. J. M and Ottmann, O. G.},
article_location = {London},
article_number = {8},
doi = {http://dx.doi.org/10.1038/s41375-019-0413-0},
keywords = {STEM-CELL TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; FUSION GENE TRANSCRIPTS; BCR-ABL TRANSCRIPTS; HARMONIZING CURRENT METHODOLOGY; TYROSINE KINASE INHIBITORS; ADULT PATIENTS; T-CELL; PERIPHERAL-BLOOD; INTENSITY CHEMOTHERAPY},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1},
url = {http://dx.doi.org/10.1038/s41375-019-0413-0},
volume = {33},
year = {2019}
}
TY - JOUR
ID - 1593316
AU - Pfeifer, H. - Cazzaniga, G. - van der Velden, V. H. J - Cayuele, J. M. - Schafer, B. - Spinelli, O. - Akiki, S. - Avigad, S. - Bendit, I. - Borg, K. - Cave, H. - Elia, L. - Reshmi, S. C. - Gerrard, G. - Hayette, S. - Hermanson, M. - Juh, A. - Jurček, Tomáš - Chillon, M. C. - Homburg, C. - Martinelli, G. - Kairisto, V. - Langen, T. - Lion, T. - Mueller, M. C. - Pane, F. - Rai, L. - Damm-Welk, C. - Sacha, T. - Schnittger, S. - Touloumenidou, T. - Valerhaugen, H. - Vandenberghe, P. - Zuna, J. - Server, H. - Herrmann, E. - Markovic, S. - van Dongen, J. J. M - Ottmann, O. G.
PY - 2019
TI - Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
JF - Leukemia
VL - 33
IS - 8
SP - 1910-1922
EP - 1910-1922
PB - Nature Publishing Group
SN - 08876924
KW - STEM-CELL TRANSPLANTATION
KW - POLYMERASE-CHAIN-REACTION
KW - FUSION GENE TRANSCRIPTS
KW - BCR-ABL TRANSCRIPTS
KW - HARMONIZING CURRENT METHODOLOGY
KW - TYROSINE KINASE INHIBITORS
KW - ADULT PATIENTS
KW - T-CELL
KW - PERIPHERAL-BLOOD
KW - INTENSITY CHEMOTHERAPY
UR - http://dx.doi.org/10.1038/s41375-019-0413-0
L2 - http://dx.doi.org/10.1038/s41375-019-0413-0
N2 - Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. Standardised use of EAC primer/probe sets and of centrally prepared plasmid standards had the greatest impact on reducing interlaboratory variability. In QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log difference were 40/67 (60%) and 52/67 (78%) at 10(-3) and 36/67 (53%) and 53/67 (79%) at 10(-4)BCR-ABL1/ABL1. Standardized RNA extraction, cDNA synthesis and cycler platforms did not improve results further, whereas stringent application of technical criteria for assay quality and uniform criteria for data interpretation and reporting were essential. We provide detailed laboratory recommendations for the standardized MRD analysis in routine diagnostic settings and in multicenter clinical trials for Ph + ALL.
ER -
PFEIFER, H., G. CAZZANIGA, V. H. J VAN DER VELDEN, J. M. CAYUELE, B. SCHAFER, O. SPINELLI, S. AKIKI, S. AVIGAD, I. BENDIT, K. BORG, H. CAVE, L. ELIA, S. C. RESHMI, G. GERRARD, S. HAYETTE, M. HERMANSON, A. JUH, Tomáš JURČEK, M. C. CHILLON, C. HOMBURG, G. MARTINELLI, V. KAIRISTO, T. LANGEN, T. LION, M. C. MUELLER, F. PANE, L. RAI, C. DAMM-WELK, T. SACHA, S. SCHNITTGER, T. TOULOUMENIDOU, H. VALERHAUGEN, P. VANDENBERGHE, J. ZUNA, H. SERVER, E. HERRMANN, S. MARKOVIC, J. J. M VAN DONGEN a O. G. OTTMANN. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. \textit{Leukemia}. London: Nature Publishing Group, 2019, roč.~33, č.~8, s.~1910-1922. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-019-0413-0.
|
